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An association between certain autoimmune conditions and increased risk of developing
lymphoma is well documented. Recent evidence points to NOTCH signaling as a strong
driver of autoimmunity. Furthermore, a role for NOTCH in various lymphomas, including
classical Hodgkin lymphoma, non-Hodgkin lymphoma, and T cell lymphoma has also been
described. In this mini-review, we will outline what is known about involvement of NOTCH
signaling in those autoimmune conditions, such as rheumatoid arthritis and primary Sjör-
gren’s syndrome, which show an increased risk for subsequent diagnosis of lymphoma.
Furthermore, we will detail what is known about the lymphomas associated with these
autoimmune conditions and how aberrant or sustained NOTCH signaling in the immune
cells that mediate these diseases may contribute to lymphoma.
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It has long been recognized that patients with particular autoim-
mune disorders and inflammatory conditions have an increased
risk for developing specific lymphomas. Generally, the link
between autoimmune diseases and developing lymphoma is cor-
relative; however, there exists a subset of autoimmune diseases for
which the risk of subsequent lymphoma development is strong
(1, 2). This review will focus on four autoimmune disorders that
have a well-established association with lymphoma occurrence:
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE),
primary Sjörgren’s syndrome (pSS), and celiac disease. We will
focus on the involvement of the NOTCH pathway in these dis-
orders, as well as the developing lymphomas, and postulate how
NOTCH signaling may be one of the pre-disposing factors in their
development.
The NOTCH family comprises four transmembrane recep-
tors (NOTCH1-4), which orchestrate multiple cell fate decisions.
NOTCH receptors engage one of five ligands, Jagged (Jag) 1, 2 or
Delta-like (DLL) 1, 3, 4, and are ultimately cleaved by γ-secretase,
liberating the signaling-competent, intracellular domain from the
membrane (NOTCHIC). NOTCHIC may then interact with pro-
teins in the cytoplasm, such as NF-κB, or translocate to the nucleus
to mediate downstream gene transcription, including the classical
targets, Hairy enhancer of split (Hes), and Hes-related with YRPW
motif [Hey; (3–5)]. NOTCH has been shown to be important
in hematopoietic lineage decisions. During lymphocyte ontogeny,
NOTCH1 promotes adoption of a T cell fate at the expense of B cell
development (6). Dysregulated NOTCH signaling is implicated
in many diseases, including autoimmune disorders and various
malignancies (7, 8).
Rheumatoid arthritis is a chronic inflammatory condition char-
acterized by painful swelling of affected joints. It has been most
strongly associated with subsequent development of diffuse large
B cell lymphoma (DLBCL), a specific type of non-Hodgkin’s
lymphoma [NHL; (1)]. Extensive evidence indicates NOTCH
signaling plays an important role in the pathogenesis of RA.
Compared to healthy joints, all four NOTCH homologs show aber-
rant expression in the inflamed synovium of RA patients (9, 10).
In particular, NOTCH1 and NOTCH3 are highly expressed, as
are the ligands DLL1 and Jag1, on the synovial lining and sub-
lining of synovial hyperplastic lesions. NOTCH1 and NOTCH3
expression overlapped with Jag1 expression (11). Moreover, in
the lymphoid follicles of these patients, NOTCH1 was detected
in T and B cells. Multiple studies have reported activated, cleaved
NOTCH1IC in the synovium and in autoreactive T cells (10–12).
Additionally, NOTCH1IC and NOTCH4IC have been found in RA
synoviocytes (13).
Inhibiting NOTCH signaling ameliorates pro-inflammatory
responses in RA. Blocking NOTCH cleavage using γ-secretase
inhibitors (GSI) reduces Th1- and Th17-mediated inflammatory
responses in vitro, as well as in a mouse model of RA (14). GSI
or NOTCH3-neutralizing antibodies can reduce T cell prolifer-
ation and pro-inflammatory cytokine production (15). GSI also
reduces TNF-induced IL-6 production and cell proliferation in
RA synoviocytes (12, 16). These data provide evidence NOTCH
signaling is important for RA progression by regulating cytokine
production and cell proliferation.
The mechanism(s) by which NOTCH signaling is sustained or
how it acts to facilitate RA progression remains an area of active
investigation. Samples from RA patients incubated with TNF
upregulated NOTCH and ligand expression (12, 13, 16). Inter-
estingly, individual NOTCH ligands have differential effects on
proliferation and cytokine production by RA cells. Culturing cells
with DLL1 promotes T cell proliferation and pro-inflammatory
cytokine production in RA (15, 16). Conversely, administering
www.frontiersin.org February 2015 | Volume 5 | Article 51 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kuksin and Minter NOTCH as a link between autoimmunity and lymphoma
soluble Jag1 provides a negative signal to CD8+ T cells and reduces
disease symptoms in a mouse model of RA (17). NOTCH may also
be acting to regulate NF-κB activation in synoviocytes. Nuclear
NOTCH1 has been shown to form a complex with RBP-Jκ and
reverse NF-κB2 promoter suppression (18). Collectively, these
date provide clear evidence NOTCH signaling is important for
the pathogenesis of RA.
Although not as tightly linked as for patients with RA, patients
with SLE also display an increased risk of developing DLBCL and
classical Hodgkin’s lymphoma [cHL; (1)]. Autoimmune SLE is
characterized by the production of autoantibodies and immune-
complex deposition that affect multiple organs. Increased num-
bers of macrophages, termed “M2b” that are defined by a sig-
nature profile of high IL-10/TNF/IL-1β/IL-6/MCP-1 production
and low IL-12 secretion have been described in SLE (19). M2b
macrophages also express high levels of NOTCH1IC as well as ele-
vated Hes1 and Hey1. Furthermore, GSI treatment in a mouse
model of SLE impaired macrophage differentiation into the M2b
phenotype and ameliorated lupus-associated symptoms, which
included reduced anti-dsDNA titers, decreased kidney scores, and
attenuated IgG deposition (19). It is not exactly known how
NOTCH signaling may be driving this pro-inflammatory response,
but macrophages stimulated by activated, lymphocyte-derived
self-apoptotic DNA (ALD-DNA) enhanced NOTCH1 signaling
and was accompanied by increased nuclear translocation of NF-
κB p50. In contrast, GSI treatment strongly downregulated NF-κB
activity, supporting the notion that NOTCH1 is driving NF-κB
associated pro-inflammatory responses in M2b macrophages (19).
In addition to its implication in M2b macrophage differentia-
tion, NOTCH signaling may also play an important role in autore-
active lymphocytes associated with SLE. GSI treatment decreased
CD4+ T cell proliferation in the lymph nodes and spleen, and low-
ered cytokine secretion and monocyte chemoattractant protein-1
(MCP-1) production (20). The authors of this report specu-
lated that inhibiting NOTCH signaling altered disease-associated
double negative T cells which, in turn, ameliorated disease symp-
toms. GSI treatment also decreased MCP-1 levels, which have
been shown to contribute significantly to the Th1 response that
drives the autoimmune manifestations in murine SLE (21–23).
In human SLE, NOTCH1 expression is downregulated in T cells
from patients with active SLE (24,25). Decreased NOTCH1 mRNA
and protein expression was determined to be due to epigenetic
modification of the NOTCH1 promoter, including histone and
CpG DNA methylation and transcriptional repression mediated
by CREMα (24). Reduced NOTCH1 expression was associated
with decreased proliferation and lower CD25 and Foxp3 expres-
sion following in vitro stimulation (25). NOTCH1 is important for
generating de novo regulatory T cells (26), and it is intriguing to
speculate that impaired NOTCH1 signaling may adversely affect
regulatory T cells in SLE, either in number or function. Abrogated
NOTCH1 signaling was also accompanied by an observed increase
in IL-17A expression in SLE patients (24). It is therefore possi-
ble that NOTCH signaling drives SLE pathogenesis by inhibiting
regulatory T cell development, thus allowing the generation of
autoreactive, IL-17A-producing T cells.
Patients with pSS experience chronic autoimmune destruction
of the exocrine glands, specifically the salivary and lacrimal glands.
Cases of pSS are associated with an increased risk of DLBCL and
marginal zone lymphoma, specifically, MALT lymphoma of the
parotid gland (1). Not much is known about the role of NOTCH
in pSS, although NOTCH2 mRNA has been detected in marginal
zone B cells in the salivary gland and in tonsil germinal centers in
pSS patients (27). Clusters of transitional type II B cells in sali-
vary glands expressed NOTCH2 and BLIMP1 mRNA and these
cells behaved like marginal zone B cells (28). Although evidence
defining a contribution for NOTCH signaling in the pathogen-
esis Sjörgren’s syndrome is not abundant, NOTCH signaling is
important in the development of salivary glands, a process, which
is defective in pSS (29). Furthermore, abnormalities in NF-κB
signaling have been observed, with polymorphisms in genes asso-
ciated with the NF-κB pathways also documented in pSS patients
(30–32). Given that NF-κB and NOTCH pathways are known
to interact, it is possible that dysregulated NF-κB signaling may
lead to dysregulated NOTCH signaling. Additional investigation
of autoimmune mechanisms that potentiate pSS will be useful to
further define any involvement of aberrant NOTCH signaling in
this disease.
As with pSS, little is known about NOTCH signaling in
celiac disease, which results from chronic immune stimulation
in response to dietary proteins in patients with a genetic predis-
position. Celiac disease is a distinctly T cell-mediated condition
and the TCRs responsible for recognizing and responding to the
inciting antigen, gliadin, a component of the gluten protein, have
been recently identified (33). Celiac disease is also associated
with development of non-Hodgkin’s T cell lymphoma. Intesti-
nal biopsies from patients with active celiac disease, including
those on a gluten free diet, revealed decreased NOTCH1 and HES1
mRNA expression in goblet cells, compared to healthy patients
(34). Furthermore, dysregulated NOTCH activity is related to the
immune-mediated pathogenesis of irritable bowel diseases, such
as ulcerative colitis and Crohn’s disease (35). Polymorphisms in the
NF-κB-related genes, REL and OLIG3/TNFAIP3 have been iden-
tified and were shown to contribute to celiac disease (36). Should
NOTCH signaling in gut T cells prove to be pathogenic in celiac
disease, a significant treatment challenge will likely result: that is
how to balance decreasing aberrant NOTCH signaling in autore-
active T cells with maintaining a healthy level of NOTCH signaling
in intestinal goblet cells (37).
A diagnosis of any of the four autoimmune diseases described
above leaves patients at increased risk of developing lymphoma
(Figure 1). It is interesting to note, however, that aggressive lym-
phocyte neoplasms are associated with these autoimmune diseases,
rather than more the indolent chronic lymphocytic leukemias (1).
DLBCL is the most common type of NHL. This fast-growing
lymphoma is characterized by large B cells that grow diffusely
throughout the lymph nodes. While NOTCH signaling has a
clear role in T cell proliferation and T cell malignancies, dysreg-
ulated NOTCH signaling in B cell lymphoma is more contro-
versial (38). The TMD8 cell line was developed from a patient
with DLBCL. These cells express NOTCH1, NOTCH2, Jagged1,
DLL4, and constitutively express HES1 mRNA. Most DLBCLs
express Epstein–Barr proteins (EBNA2), which mimic NOTCH
signaling to promote HES expression. However, TMD8 cells do
not express EBNA2; therefore, the constitutive HES1 expression
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FIGURE 1 | Potential association of autoimmune conditions and
lymphoma. Schematic showing four autoimmune diseases (green boxes,
left side) associated with increased risk for developing lymphomas [blue
boxes, right side; (1, 2)]. The arrows indicate correlation between specific
autoimmune diseases and most frequently associated lymphoma. NOTCH
signaling component(s) dysregulated in autoimmune conditions or
lymphoma is indicated under each box.
is thought to be driven by NOTCH signaling. Treating this cell
line with GSI impaired cell growth and reduced expression of
HES1. However, one caveat of this study is that GSI did not fully
inhibit NOTCH1 cleavage, which might indicate a slow rate of
NOTCH1 protein degradation. Alternatively, the biological effects
seen may result from GSI acting on another target of γ-secretase,
such as NOTCH2; however, NOTCH2 cleavage after GSI treatment
was not assessed (39). Although NOTCH1IC could be detected
in the TMD8 cell line, a tissue microarray containing 68 well-
characterized DLBCLs revealed none that stained positively for
NOTCH1IC (40). This may suggest that family members other
than NOTCH1 are dysregulated in these tumors, but more stud-
ies are needed to ascertain the degree to which activated NOTCH
drives DLBCL.
In studies of patients with DLBCL, mutations in the het-
erodimerization and PEST domains of NOTCH2 were found in
a small (8%) percentage. Of this cohort, 40% had increased copy
numbers of the NOTCH2 allele carrying the PEST domain muta-
tion, and in one patient the total copy number of NOTCH2
was increased. Furthermore, mutant NOTCH2 receptors showed
increased activity when stimulated with NOTCH ligands in vitro
(41). A SNP variation in 13q12,which contains the NOTCH signal-
ing mediator, LNX2, has also been identified. This gene encodes a
PDZ domain-containing zinc finger 1 protein, which may function
as an E3 ubiquitin ligase. Elevated levels of LNX family mem-
bers were shown to promote ubiquitin–proteasomal degradation
of the NOTCH negative regulator, NUMB, resulting in enhanced
NOTCH signaling (42). NF-κB expression and activation is also
high in DLBCL tumors (43–46). Thus, both NOTCH and NF-κB
may play a role in DLBCL progression.
Classical Hodgkin’s lymphoma is characterized by the pres-
ence of very large cells called Hodgkin and Reed-Sternberg (HRS)
cells, although other abnormal cell types may also be present.
NOTCH signaling has been shown to play a prominent role in cHL
pathogenesis. NOTCH1 and NOTCH2 are aberrantly expressed in
HRS cells and are stimulated through Jagged1 to promote prolif-
eration and protect from apoptosis (47). HRS cells are known to
express Jagged1, Jagged2, DLL1, DLL3, and DLL4 (47, 48). Finally,
an absence of the NOTCH1 inhibitor DELTEX1, together with
increased expression of the NOTCH co-activator, MAML, likely
drive NOTCH signaling in HRS cells (48, 49).
NOTCH and NF-κB signaling pathways have been shown to
cooperate, resulting in cHL pathogenesis. HRS cells are character-
ized by high levels of nuclear NF-κB p50/p65 dimers, which are
required for proliferation, protection from apoptosis, and growth
in lymphoma mouse models (50–52). In addition, mutations in
NF-κB regulators, such as IκBα, IκBε, or IκB kinase (IKK)α, con-
tribute to constitutive activation of canonical NF-κB signaling
in HRS cells (51, 53, 54). Inhibiting NOTCH activity in HRS
cells using GSI induces apoptosis through simultaneous targeting
of the NOTCH and alternative NF-κB signaling pathways (55).
Thus, NOTCH signaling conspires to drive cHL pathology and
inhibiting NOTCH signaling may have positive implications for
treatment.
MALT lymphoma of the parotid gland represents a small sub-
set of head and neck NHL. A diagnosis of Sjörgren’s syndrome is
associated with a 1000-fold increase in the risk of parotid gland
marginal zone lymphoma (56). Although no studies have explored
how NOTCH signaling may contribute to development of MALT
lymphoma of the parotid gland, there have been studies exam-
ining MALT lymphoma in the spleen (SMZL). In 30% of SMZL
cases, alterations in genes of the NOTCH pathway emerged as
highly recurrent. NOTCH2, a key regulator of marginal zone B
cell development, was identified as the most frequently mutated
gene, occurring in approximately 20% of cases, often result-
ing in disruption of the PEST domain (57–59). In addition to
NOTCH2, genetic lesions in other modulators or members of
the NOTCH pathway were also observed in SMZL, including
SPEN, DELTEX1, and NOTCH1 (58). Mutations in members of
the NF-κB pathway have also been implicated in MALT lym-
phoma (60–62). In fact, somatic mutations of TNFAIP3 (A20)
protein, which plays a key role in controlling NF-κB activation,
have been observed in the MALT lymphoma subtype frequently
associated with SS (60). More studies are needed to ascertain
whether and how NOTCH signaling drives MALT lymphomas
associated with pSS.
The majority of systemic autoimmune diseases predispose
to developing lymphomas of B cell origin. However, patients
with autoimmune diseases of the gastrointestinal tract, such as
celiac disease, exhibit a higher risk of NHL T cell lymphoma
(63), a subset of NHL arising from a single T cell clone. Muta-
tions in NOTCH1 have been found with high frequency in all
major oncogenic subclasses of human T cell lymphomas, sug-
gesting NOTCH1 plays a significant role in lymphomagenesis
(64). In a small study, half of the T cell lymphomas examined
carried activating NOTCH1 mutations and/or mutations in the
NOTCH-inhibiting FBXW7, which encodes an ubiquitin ligase
that degrades NOTCH (65, 66). In addition,NOTCH3 mRNA has
also been noted in patients with T cell lymphoma, and thymocyte-
specific NOTCH3IC transgenic mice develop T cell lymphoma
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of the spleen and lymph nodes (67, 68). Interestingly, NOTCH2
mRNA has been shown to be decreased in γ-irradiation-induced T
cell lymphomas (69). T cell lymphomas treated in vitro with GSI
showed growth inhibition and caspase-mediated apoptosis (65,
70). A role for NOTCH–NF-κB interaction has been described
in mouse models of T cell lymphoma (67), and elevated NF-κB
activity in the primary cells of patients with T cell lymphoma
has been described in cases of acute but not chronic disease (71).
As with other types of lymphomas discussed here, NOTCH sig-
naling appears to play an important role in T cell survival in
lymphomas (47).
Patients with certain autoimmune diseases face an increased
risk of developing aggressive lymphomas. Based on the evidence
presented here, we suggest that dysregulated NOTCH signaling
is implicated both in the autoimmune responses and the associ-
ated lymphomas. Chronic antigenic stimulation and inflamma-
tion define the immunological environment of autoimmunity
and are factors that can precipitate the onset of lymphoma.
Furthermore, convergence of the NOTCH and NF-κB signaling
pathways likely promote both the pro-inflammatory environ-
ment and transformation of stimulated clones. Inhibiting the
NOTCH pathway in autoimmune disease may act to attenu-
ate both conditions since NOTCH signaling may be a mediator
both of the autoimmune process and the lymphomas that arise
subsequently.
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